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Abstract objectives A growing evidence base implicates human cytomegalovirus (HCMV) as a risk factor
for TB disease. We investigated total IgG and mycobacteria-specific antibodies in a cross-sectional
study nested within a rural Ugandan General Population Cohort (GPC), in relation to HIV infection
and the magnitude of HCMV IgG response.
methods Sera from 2189 individuals (including 27 sputum-positive TB cases) were analysed for
antibodies against mycobacteria (Ag85A, PPD, LAM, ESAT6/CFP10) and HCMV, tetanus toxoid
(TT) and total IgG.
results Anti-mycobacterial antibodies increased with age until approximately 20 years, when they
plateaued. Higher HCMV exposure (measured by IgG) was associated with lower levels of some anti-
mycobacterial antibodies, but no increase in total IgG. HIV infection was associated with a decrease
in all anti-mycobacterial antibodies measured and with an increase in total IgG.
conclusions The increase in anti-mycobacterial antibodies with age suggests increasing exposure to
non-tuberculous mycobacteria (NTM), and to M.tb itself. HIV infection is associated with decreased
levels of all mycobacterial antibodies studied here, and high levels of HCMV IgG are associated with
decreased levels of some mycobacterial antibodies. These findings point towards the importance of
humoral immune responses in HIV/TB co-infection and highlight a possible role of HCMV as a risk
factor for TB disease.
keywords TB, HIV, HCMV, Mycobacterium
Introduction
The role of antibody-mediated immunity in TB has not
been fully elucidated (reviewed in [1]). Despite the impor-
tance of cell-mediated Th1 responses in TB disease [2, 3],
attempts to stimulate this arm of the human immune
response by vaccine developers have not translated into
protection from disease in human efficacy trials [4, 5],
and there may be useful humoral correlates of disease or
protection yet to be identified.
A growing evidence base for the importance of anti-
bodies in protection against other intracellular pathogens
such as Listeria monocytogenes [6] and Salmonella spp.
[7] has led to renewed interest in humoral responses to
TB and the factors which may affect them. Recent work
has suggested a potential protective role of antigen 85A
(Ag85A)-specific antibodies in reduced TB disease risk in
BCG-vaccinated South African infants [8, 9].
It is known that TB and HIV work synergistically to
exacerbate morbidity and mortality in co-infected individ-
uals with respect to both diseases [10]. Epidemiologically,
concomitant viral infections other than HIV are known
to be associated with poor TB outcomes. In Taiwan
Hepatitis C infection was associated with a higher risk of
developing active TB disease [11], and in South Africa
influenza/TB co-infection was associated with increased
mortality [12]. A large TB vaccine trial in South Africa,
which investigated correlates of TB disease risk or protec-
tion, found an association between CD8 T-cell activation
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and HCMV response [8] that was linked to an increased
risk of TB disease and shorter time to diagnosis [13].
The ubiquitous herpes virus HCMV is known to cause
immune activation [14], immune senescence [15], and is
a significant factor in immune variation [16]. Recently,
our group has reported elevated levels of HCMV IgG
among TB patients compared to controls [17]. Despite
this, and the findings of some early epidemiologic studies
[18, 19], data linking HCMV and TB are sparse.
To investigate mycobacteria-specific antibody levels
across ages, and to examine potential effects of HCMV
co-infection on antibody levels, this study tested 2187
stored serum samples (of which 27 were active TB cases)
from a rural Ugandan cohort for IgG responses to
Ag85A, purified protein derivative (PPD), lipoarabino-
mannan (LAM) and CFP10/ESAT6, along with IgM
responses to Ag85A. These antigens were chosen based
on availability, evidence of their potential importance in
TB disease from the literature (Ag85A [9], LAM [20, 21],
PPD [22]), and specificity to M.tb (CFP10/ESAT6 [23]).
Seropositivity to HCMV was measured and existing data
on HIV, BCG vaccination status, as well as demographic
information was matched and investigated for associa-
tions. Responses to tetanus toxoid (TT) and total IgG
levels were also investigated as control antibodies.
Materials and methods
Study area and design
The General Population Cohort (GPC) is a population-
based open cohort study in rural south-western Uganda,
administered by the Medical Research Council (MRC)
UK in collaboration with the Uganda Virus Research
Institute (UVRI) [24]. The cohort comprises a cluster of
25 neighbouring villages with approximately 20 000 resi-
dents (52% aged <13 years) from three ethnic groups,
the majority (75%) being from the Baganda tribe, the
main tribal group in the region. Data are collected
through an annual census, questionnaire and serological
survey (further details on questions included in the census
can be found in a publication by Asiki et al. [24]).
Demographic information was collected at the same time
as the blood samples. Blood specimens were obtained
and immediately tested for HIV-1. Samples with incon-
clusive results were retested. Remaining sera were stored
at 80 °C. All samples used for this study, except active
TB cases, were collected from adults and children in GPC
round 22, conducted in 2011. Active TB cases were diag-
nosed through positive sputum smear microscopy after
passive case detection and were sampled from a range of
GPC rounds between 1999 and 2014. Sera collected as
close as possible to the time of TB diagnosis were used
for this study (between 5 years prior to, and 0.8 years
after diagnosis of active TB diagnosis).
Sampling
Individuals were selected for inclusion in this cross-sec-
tional study at random after stratification by age and sex.
Due to anticipated high levels of HCMV seropositivity,
infants under the age of 5 were oversampled. Individuals
were only sampled once and siblings and parent-child
pairs were not excluded. The total planned sample size
was 2000, plus 10% oversampling. A target of approxi-
mately 100 individuals per year of age up to 5 years, 200
individuals aged 6–10, 11–15 and 16–20, 200 in subse-
quent 10-year intervals up to 60 years and 200 people
aged 61 years or over. The sex ratio was approximately
equal within each age group (Table 1).
Ethics
Written consent or assent in conjunction with parental/
guardian consent for those younger than 18 years were
obtained following Uganda National Council of Science
and Technology (UNCST) guidelines before all survey
procedures [24]. Written consent/assent was also
obtained from participants on the use of their clinical
records and stored biological samples for research
purposes.
Ethical approval for the use of GPC samples for this
study was obtained from the UVRI Research and Ethics
Committee and from the UNCST, in addition to the Lon-
don School of Hygiene & Tropical Medicine (LSHTM),
London, UK.
Serology: Ag85A, PPD, LAM, CFP10/ESAT6 and TT
Antibody content was measured using ELISA. Experi-
menters were blind to exposure group for all samples.
Testing was conducted at UVRI in Entebbe, Uganda
(Ag85A IgG and PPD IgG) and LSHTM, London, UK
(CFP10/ESAT6 IgG, Ag85A IgM, LAM IgG and TT
IgG). Half volume ELISA plates (Fisher Scientific) were
coated overnight at 4 °C with sodium carbonate buffer
containing 1.5 lg/ml recombinant Ag85A protein (Aeras,
USA), 1.5 lg/ml PPD (Lot 051815KA, Aeras, USA),
0.5 lg/ml TT (02/232, NIBSC, UK), 0.5 lg/ml LAM
(NR-14848, BEI Resources, VA, USA), 0.25 lg/ml each
CFP10 (NR-49425, BEI Resources, VA, USA) and ESAT6
(NR-14868, BEI Resources, VA, USA). Plates and
reagents were brought to room temperature and the plate
was washed three times with PBS, 5% Tween20 (v/v)
(PBST). After blocking with PBS 5% milk (w/v) blocking
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buffer, duplicate 1:100 test serum, high and low PPD
responder controls and plate blanks consisting of assay
diluent alone with no serum were added in triplicate.
Incubation for 2 h at room temperature and washing
with PBST was followed by a one hour incubation with
an appropriately diluted peroxidase-conjugated secondary
antibody in PBST-5% (IgG, 1:500 dilution of goat anti-
human IgG-HRP (04-10-20, KPL, USA); IgM, 1:10 000
dilution of goat anti-human IgM-HRP (Abcam ab97205,
RRID: AB_10695942)). After washing with PBST, 50 ll
tetramethylbenzidine (TMB, BD BioSciences, USA) was
added to each well. The plate was incubated for 15 min
in the dark before the reaction was stopped by adding
50 ll of 2M Sulphuric Acid (Sigma, USA) to each well.
Absorbance was measured at 450 nm within 30 min to
obtain optical density (OD), a surrogate marker of anti-
body titre.
Mean blank values were subtracted from all OD read-
ings, and geometric means of duplicates were used to
reduce the effect of skewed distribution. Median levels
with interquartile ranges (IQR) are used for graphical
representation of antibody levels in Figures 1 and 2.
Total IgG serology
All samples were tested for total IgG content at LSHTM.
As above, half volume ELISA plates were coated over-
night with mouse anti-human IgG at 0.5 lg/ml (Abcam
ab200699). IgG antibody standards (134.4–8.4 ng/ml)
were prepared by diluting purified human IgG (Sigma
I4506, RRID:AB_1163606) in PSBT-5% milk and test
sera were diluted 8 9 105 in PBST-5% Milk. Duplicate
test samples, controls and blanks were incubated for one
hour at 37 °C, and, after washing, samples incubated
with peroxidase-conjugated goat anti-human Fc (Abcam
ab97225, RRID: AB_10680850) diluted 1/500 with
PBST-5% Milk for one hour at room temperature. Plates
were developed with TMB, and sulphuric acid was added
to stop the reaction. Plates were read at 450 nm and OD
measurements converted into g/l by use of the standard
curve on each plate.
Serology HCMV
Samples were tested for IgG antibodies against HCMV
using a commercial ELISA kit (Novatec Immunodiagnos-
tica GmbH) according to kit instructions (described in
[17]).
Statistical analysis
Correlations between each pair of mycobacterial antibody
OD levels were conducted using Spearman’s rho. Because
of the ubiquity of HCMV infection within this popula-
tion [17], analysis was conducted on the HCMV-seropo-
sitive population only.
Individuals seropositive for HCMV IgG were further
categorised into three groups according to the tertiles of
HCMV antibody concentrations (measured by OD): low,
medium and high.
Linear regression was used to determine the association
of each antibody response (as continuous dependent
Table 1 Characteristics of study partici-
pants (HCMV seropositive individuals by
age group (n = 1988)). Sex, HIV infec-
tion, BCG vaccination and TB case preva-
lence is shown for each age group
Age
group
(year) n
Sex (percentage
female
(number/total))
HIV prevalence,
percentage
(number/total)
BCG vaccinated,
percentage
(number/total)
Active TB
cases,
percentage
(number/total)
<1 75 47% (35/75) 4% (3/73) 76% (54/71) 0% (0/75)
1 83 51% (42/83) 1% (1/80) 96% (73/76) 0% (0/83)
2 82 52% (43/82) 1% (1/78) 90% (63/70) 0% (0/82)
3 87 47% (41/87) 1% (1/85) 93% (70/75) 0% (0/87)
4 100 52% (52/100) 0% (0/97) 94% (82/87) 0% (0/100)
5 106 54% (57/106) 1% (1/101) 8% (80/90) 0% (0/106)
6–10 183 47% (86/183) 1% (2/175) 90% (135/150) 0% (0/183)
11–15 192 49% (94/192) 0% (0/187) 81% (125/155) 1% (1/192)
16–20 204 51% (105/204) 1% (3/204) 69% (132/190) 0.5% (1/204)
21–30 216 56% (120/216) 9% (19/216) 70% (128/184) 2% (5/216)
31–40 238 52% (123/238) 13% (31/238) 57% (119/209) 4% (10/238)
41–50 166 45% (74/166) 15% (25/166) 52% (75/145) 4% (6/166)
51–60 109 49% (53/109) 6% (7/109) 53% (52/98) 4% (4/109)
61+ 147 46% (68/147) 1% (2/147) 26% (37/144) 0% (0/147)
Total 1988 50% (993/1988) 5% (96/1956) 70% (1225/1744) 1.4% (27/1988)
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variables) with HCMV IgG tertile and HIV infection (as
independent variables with HCMV as a categorical vari-
able), adjusting for age and sex. BCG vaccination status
and active TB disease were also included in the regression
model, however as 89% (24/27) of active TB cases had
unknown BCG status, it was not possible to include both
variables in the same model. The model including TB
was preferred, with the model including BCG run as a
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comparison to confirm the consistency of the results.
BCG vaccination was included in a separate regression
analysis using the same model.
Individuals with unknown HIV status were excluded
from all regression analyses and individuals with
unknown BCG vaccination status were excluded from
regression analyses including BCG. To account for evi-
dence of non-linearity of antibody OD with age (likeli-
hood ratio test P < 0.001 for all antibodies), a quadratic
term for age was included in the regression analyses.
Numbers included in each of the regression analyses are
shown in Tables 2 and 3.
To account for multiple comparisons, 99% confidence
intervals (CIs) are reported and a P value of 0.01 was
considered to represent strong evidence to reject the null
hypothesis. Due to different dynamic ranges of spec-
trophotometers used in Uganda and the UK, antibody
OD measurements (for mycobacterial antibodies only)
were rescaled for graphical representation. This was
done by subtracting the minimum value within the range
from each value, dividing by the range for that antibody
and multiplying by 100; hence Figure 1 shows the per-
centage of the maximum OD. All analyses were per-
formed on raw data using Stata version 14 (Stata
Corporation, College Station, TX, USA). Anonymised
participant data are available.
Results
Sera were sampled from 2189 individuals. Total IgG
levels could not be determined in 15 instances, likely due
to protein degradation. Of the remaining 2174 individu-
als, 8.6% (186/2174) were HCMV-seronegative and were
excluded from analysis. The HCMV-negative population
contained no TB cases and 4 HIV-positive individuals.
Ninety-eight (53%) were female and the mean age was
14.6 years (range 3 months–95 years).
The remaining 1988 individuals were included in fur-
ther analyses. The mean age was 23.4 years (range
30 days–100 years) and 50% were female (Table 1).
Ninety-eight per cent (1956/1988) of individuals had a
conclusive HIV result, and of those, 4.9% (96/1956)
were HIV-positive, with the greatest proportion in the
31–50 year age group.
Twenty-seven sputum-confirmed TB cases were
included in the study, of whom 63% (17/27) were female
and whose mean age was 36 years (range 12–59 years).
Only three TB cases had BCG vaccination information
and all of those were unvaccinated. All 27 were HCMV-
seropositive, with 59% (16/27) having HCMV IgG levels
in the upper tertile.
Antibody responses
IgG against Ag85A, PPD, LAM, CFP10/ESAT6 and IgM
against Ag85A all increased from birth to approximately
20 years of age, after which OD values reached a pla-
teau. Figure 1 shows median OD for each of the
mycobacterial antibody levels by age group. Initial levels
in infants under the age of one year range from a median
of 4% of maximum OD (0.12 OD) for Ag85A IgM to
12% of maximum OD (0.35 OD) for LAM IgG.
Responses to the M.tb-specific ESAT6/CFP10 antigens
did not show the same rapid increase from birth as
responses to other mycobacterial antibodies. The highest
10% of responders in terms of CFP10/ESAT6, being
M.tb specific antigens, were investigated further and there
was no evidence of a difference in proportion of TB cases or
HIV positive individuals compared with the lowest 10%.
Univariate analysis showed no differences in mean OD
levels by sex. Analysis of correlation showed a high
degree of co-linearity between all mycobacterial antibod-
ies (0.33> rho <0.65, all P < 0.001). OD ranged from
0.002 to 1.793 OD for Ag85A IgG, 0.000 to 1.930 OD
for PPD IgG, 0.004 to 2.961 OD for LAM IgG, 0.005 to
2.927 OD for CFP10/ESAT6 IgG and 0.001 to 2.926
OD for Ag85A IgM.
Tetanus toxoid and total IgG levels were investigated
as control antibodies (Figure 2). TT vaccination induces
high levels of TT IgG and is given at birth and to preg-
nant females as part of the Uganda immunisation sched-
ule [25]. TT IgG showed high levels of antibody from
birth and a clear sex difference with females having
higher overall IgG levels (P < 0.001, Figure 2a). This
difference is driven by females aged between 16 and
50 years (Figure 2a). Total IgG levels increase with age
from birth (median 46.2 g/l in infants less than one year
of age) to a plateau after 11 years of age (median
69.4 g/l), Figure 2b. Since a univariate analysis of total
IgG by sex indicated no difference, data were not sepa-
rated by sex for this plot.
In a multivariable linear regression model including TB
disease status, being HIV-positive was associated with a
decrease in all mycobacterial antibody levels studied
(magnitude ranged from mean decrease in 0.240 OD
(99% CI 0.361, 0.119) for IgG against Ag85A), to a
mean decrease in 0.446 OD (99% CI 0.640, 0.251)
for IgM against Ag85A, all P < 0.001, Table 2). Simi-
larly, being in the upper tertile of HCMV IgG response
was associated with a decrease in Ag85A, PPD and LAM
IgG levels compared to being in the middle tertile: a
mean decrease in 0.067 OD (99% CI 0.122, 0.012) for
Ag85A IgG, 0.057 OD (99% CI 0.105, 0.009) for
PPD IgG and 0.107 (99% CI 0.194, 0.019) for LAM
© 2018 The Authors. Tropical Medicine & International Health Published by John Wiley & Sons Ltd. 5
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IgG (all P < 0.001, Table 2). While the direction of
change was the same for CFP10/ESAT6 IgG and Ag85A
IgM, the mean decrease associated with being in the
upper tertile of HCMV IgG response was not sufficiently
large to provide good evidence of a difference based upon
our significance threshold (Table 2). The association
between mycobacterial antibody levels and magnitude of
HCMV IgG response was not linear (Figure 3): in com-
parison to the middle tertile of HCMV IgG response, the
lowest tertile was also associated with a decrease in
mycobacterial antibody levels. A mean decrease of 0.100
OD (99% CI 0.156, 0.044) P < 0.001 was seen for
CFP10/ESAT6 IgG and a mean decrease of 0.104 OD
(99% CI 0.205, 0.004) P = 0.01 for Ag85A IgM. The
direction of change was the same for the remaining
mycobacterial antibodies (Table 2).
Being a sputum-confirmed active TB case was not asso-
ciated with any differences in any mycobacterial antibody
level after adjusting for age, sex, HIV and HCMV level,
although given that there were only 27 cases, there was
limited statistical power to detect associations (Table 2).
Coefficients of the effect of HIV and HCMV for each
outcome measurement were similar for a model including
BCG instead of TB, and the magnitude of effect was not
altered by adjusting for total IgG. Being BCG vaccinated
was associated with a 0.115 OD increase in TT IgG
(99% CI 0.004–0.227) P = 0.01.
Table 3 shows that HIV positivity was associated with
an increase in total levels of IgG (9.110 g/l (99% CI
3.735, 14.485), P < 0.001). Being female was associated
with an increase in TT of 0.272 OD (99% CI 0.188,
0.356, P < 0.001) but no difference in total IgG levels.
While being an active TB case was not associated with
any differences in TT IgG, being a TB case was associ-
ated with a 5.8 g/l decrease (99% CI 13.298, 1.720) in
total IgG however this was not significant (P = 0.05).
The magnitude of HCMV IgG response did not affect
either total IgG levels or TT IgG response (Table 3).
Discussion
In this study, we found that HIV infected individuals had
decreased levels of all mycobacterial antibodies studied,
with a concomitant increase in total IgG. We also found
that individuals with the highest levels of HCMV IgG
(indicative of highest exposure [26, 27]), had decreased
levels of IgG specific for Ag85A, PPD and LAM, but had
no corresponding change in total IgG levels. Previously
our group has shown that TB patients have increased
levels of HCMV IgG [17] and that HCMV positive
infants (as measured by HCMV IFN-c ELISPOT) were at
higher risk of progressing to active TB disease [13].
HCMV infection, being linked to poor long-term health
outcomes [28, 29] and large immune system subversion
[16, 30], may be acting to manipulate mycobacterial anti-
bodies which may be contributing to protective mecha-
nisms against M.tb infection.
As has been seen previously [31], humoral responses
against RD1 antigens ESAT6 or CFP10 (mycobacterial
proteins associated specifically with M.tb and not NTM
or BCG) did not show an association with active TB
cases in this study. Due to a lack of active TB case-find-
ing in the GPC, it is likely that some of the individuals
classed as TB negative here were latently infected with
Table 3 Multivariable linear regression of variables with a potential influence on total IgG and TT-specific IgG levels. Values obtained
using a multivariable regression model including age, quadratic age, sex, HIV and TB status, with P value and 99% CI (n = 1956)
Variable n (%)
Total IgG (g/l) TT IgG OD
Coeff (99% CI) P value Coeff (99% CI) P value
Sex
Male 978/1956 (50.0%) Baseline Baseline
Female 978/1956 (50.0%) 0.326 (2.350, 1.697) 0.68 0.272 (0.188, 0.356) <0.001
HCMV tertiles
HCMV low 650/1956 (33.2%) 0.318 (2.240, 2.877) 0.75 0.090 (0.187, 0.008) 0.02
HCMV medium 650/1956 (33.2%) Baseline Baseline
HCMV high 656/1956 (33.5%) 0.915 (1.508, 3.338) 0.33 0.065 (0.029, 0.159) 0.08
HIV status
Negative 1860/1956 (95.1%) Baseline Baseline
Positive 96/1956 (4.9%) 9.110 (3.735, 14.485) <0.001 0.172 (0.357, 0.012) 0.02
TB status
Negative 1929/1956 (98.6%) Baseline Baseline
Positive 27/1956 (1.4%) 5.789 (13.298, 1.720) 0.05 0.081 (0.328, 0.165) 0.4
CI, confidence interval; OD, optical density.
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M.tb based on epidemiologic data on exposure in Uganda
[32, 33]. The finding that IgG responses to these M.tb-
specific antigens increase with age, following a similar
pattern as other non-M.tb-specific mycobacterial antibod-
ies, suggests that while NTM may be driving high
responses of acute (IgM) and sustained (IgG) mycobacte-
rial responses, exposure to M.tb itself cannot be ignored.
BCG vaccine status allocation in this study was by the
presence of scar, inspection of immunisation card or ver-
bal confirmation by parent of guardian. Despite issues
with these methods [34], classification was thought to be
robust due to the evidence of association of TT IgG with
BCG indicating that people vaccinated for one Extended
Programme of Immunization (EPI) schedule vaccine are
more likely to have received other vaccinations upon
accessing local health centres.
The magnitude of difference in mycobacterial antibod-
ies seen due to HIV infection was far greater than due to
either active TB disease or BCG vaccination. The lower
levels of mycobacterial antibodies seen in individuals
infected with HIV is accompanied by an increase in total
IgG. The effect seen here points towards HIV infection
having a mycobacteria-specific effect as opposed to a
more general depression of all antibody levels, thereby
confirming evidence seen previously in a much smaller
number of patients in Italy [35]. It is known that HIV
preferentially depletes TB-specific CD4 T cells [36].
Through their absence, TB-specific T cells would not pro-
vide signals to B cells in order for them to proliferate and
differentiate into immunoglobulin-secreting plasma cells.
As far as we are aware, the possible downstream humoral
mechanism of HIV-associated TB-specific T-cell depletion
has not been investigated.
Here we see a similar association between the highest
levels of HCMV IgG, and decreased levels of some
mycobacterial antibodies. This is not accompanied by a
decrease in total IgG or TT IgG. As a human herpes
virus, HCMV persists in a variety of cell types in a dor-
mant state and is transmitted through body fluids [37].
Infection is not normally associated with symptomatic
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disease; however, it poses a huge burden on the immune
system, with maintenance of up to 30% of both CD4
and CD8 circulating memory T cells being specific to
HCMV [38]. The virus is a significant factor in immune
variation [16], immunosenescence [15] and causes
immune activation [39], including non-specific polyclonal
B-cell activation and proliferation [40].
In this study, we see decreased mycobacterial antibody
levels at both HCMV IgG extremes among HCMV
seropositive individuals. Evidence of HCMV effect on
vaccine responses exists, showing both a detrimental
impact of HCMV infection [41, 42] and a positive, ‘adju-
vanting’, effect of HCMV on vaccine-induced antibody
responses in humans [43]. Given reports that cellular
responses to heterologous virus challenge in mice may
depend on the initial viral dose of HCMV [44, 45] the
lack of a linear response between HCMV IgG and
mycobacterial antibody levels seen in this study may also
be indicative of different effects at different HCMV expo-
sure levels. PBMC samples were not available from this
cohort for us to determine if the magnitude of HCMV
IgG level had a similar impact on the mycobacteria-speci-
fic cellular immune response. However, it is likely that
cellular immunity is also impacted by HCMV given that
HCMV has been shown to affect both humoral and cell-
mediated immune responses to vaccine antigens [46, 47].
Before the widespread use of highly active anti-retrovir-
als (HAART), HCMV/HIV co-infection saw HCMV as
an important cause of severe non-AIDS events, including
death, in HIV-infected individuals [48]. High levels of
HCMV IgG, caused by repeated reactivation or reinfec-
tion events, are associated with higher all-cause mortality
[49] and lower CD4 cell count, with accompanying
worse response to anti-retrovirals [50]. Despite literature
describing HCMV-induced B-cell activation [40, 51, 52],
in this study we saw no relationship between HCMV
exposure and increased levels of total IgG. We do how-
ever see a trend towards decreased mycobacterial anti-
body response in individuals with very high HCMV IgG
responses after adjusting for HIV infection. Considering
the risk of developing active TB disease increases over 20
times in individuals with HIV [53], it is likely that any
added effect of HCMV would be masked. The mycobac-
terial antibody-specific decrease seen with both HIV
infection and, independently, in the highest tertile of
HCMV exposure, may be indicative of a functional, pro-
tective role of mycobacterial-specific antibodies which are
independently decreased by HIV and high levels of expo-
sure to HCMV.
In summary, both HIV infection and high levels of
HCMV IgG were both associated with decreases in
mycobacterial antibody levels. Given this novel finding of
effect of HCMV exposure on mycobacterial antibody
levels, investigation of magnitude of HCMV may be
important in future TB clinical trials to understand the
immune environment, independently of HIV infection sta-
tus. In addition to quantification of antibody levels, we
believe that it will be important to measure HCMV effect
on mycobacteria-specific cellular responses. A more
nuanced understanding of the quality, as well as the
quantity, of the mycobacterial antibodies elicited, in
terms of antibody class, subtype and avidity may help to
shed light upon a potential mechanism by which they
might confer protection to host cells.
Due to insufficient volumes of sera, we were unable to
investigate HCMV viral load in serum samples to ascer-
tain whether active infection at point of blood draw was
associated with any of the measurements taken for this
study. Despite this, we believe that the use of HCMV-spe-
cific IgG is a robust a measure of cumulative exposure. As
previously mentioned, active TB case finding is not carried
out within the GPC and therefore we cannot be sure that
some individuals analysed as ‘non-TB’ are not latently
infected. PBMC samples were not available from this
cohort for us to determine if HCMV had a similar impact
on the mycobacterial cellular immune response.
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